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ABSTRACT
In the search of facile and efficient methods for
cellular delivery of peptide nucleic acids (PNA),
we have synthesized PNAs conjugated to oligo-
phosphonates via phosphonate glutamine and bis-
phosphonate lysine amino acid derivatives thereby
introducing up to twelve phosphonate moieties into
a PNA oligomer. This modification of the PNA
does not interfere with the nucleic acid target bind-
ing affinity based on thermal stability of the PNA/
RNA duplexes. When delivered to cultured HeLa
pLuc705 cells by Lipofectamine, the PNAs showed
dose-dependent nuclear antisense activity in the
nanomolar range as inferred from induced lucifer-
ase activity as a consequence of pre-mRNA splicing
correction by the antisense-PNA. Antisense activity
depended on the number of phosphonate moieties
and the most potent hexa-bis-phosphonate-PNA
showed at least 20-fold higher activity than that
of an optimized PNA/DNA hetero-duplex. These
results indicate that conjugation of phosphonate
moieties to the PNA can dramatically improve cel-
lular delivery mediated by cationic lipids without
affecting on the binding affinity and sequence
discrimination ability, exhibiting EC50 values down
to one nanomolar. Thus the intracellular efficacy
of PNA oligomers rival that of siRNA and the
results therefore emphasize that provided sufficient
in vivo bioavailability of PNA can be achieved these
molecules may be developed into potent gene
therapeutic drugs.
INTRODUCTION
Peptide nucleic acids (PNAs) (1) are attractive candidates
for the discovery and development of antisense gene
therapeutics and antigene drugs (2–4), but rapid progress
has been limited by the lack of facile and eﬃcient cellular
delivery methods (5,6).
Eﬃcient DNA (and siRNA) transfection reagents, such
as cationic lipids and polymers, are positively charged
and rely on self-assembly via complexation with the nega-
tively charged DNA. Unmodiﬁed aminoethylglycyl PNAs
(aegPNAs) are charge neutral and do not interact with
cationic lipids or polymers and consequently are not eﬀec-
tively delivered to cells by such reagents. Several modiﬁca-
tions of the PNAs have been devised in order to increase
the association of PNA oligomers with cationic lipid com-
plexes. These modiﬁcations include covalent conjugation
to lipophilic ligands [such as fatty acids (7,8) or polyhet-
eroaromates (9)], introduction of negative charges through
backbone modiﬁcation (10–12), or through use of cova-
lent PNA–DNA chimera (13) or PNA/DNA hetero-
duplexes (14). However, none of these approaches is
optimal. Conjugation of PNAs to lipophilic ligands is
straightforward, and allows cationic lipoplex delivery of
the conjugates (7,8), but unfortunately the conjugates
have poor aqueous solubility and in most cases the cellular
antisense eﬃcacy is limited. Backbone modiﬁcations of the
PNAs require synthesis of or access to a number of special
monomers and may also aﬀect hybridization eﬃciency
and speciﬁcity (12). Synthesis of PNA–DNA chimera
likewise requires elaborate synthesis, and results in oligo-
mers with compromised hybridization properties due to
the structural incompatibility between the amide PNA
and the phosphodiester DNA backbones (13). Finally,
PNA/DNA hybrid lipoplex delivery (although being
quite eﬃcient) requires additional steps in the delivery
protocol and very careful optimization of the complemen-
tary DNA sequences for each PNA (14–16). Nonetheless,
supplying PNA oligomers with negative charges in order
to assure eﬀective interaction with cationic (lipid) cellular
delivery agents is indeed an attractive approach provided
that uncompromised hybridization characteristics and
mismatch discrimination are maintained. We reasoned
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an oligo–phosphate ligand could adequately serve this
purpose. In principle phosphorylated peptides containing
e.g. phosphoserine or phosphotyrosine could be exploited,
but as these are both chemically and biologically
unstable—being prone to (enzymatic) hydrolysis—we
decided to explore the possibilities of using more stable
phosphonate compounds. Thus we have synthesized a glu-
tamine phosphonate and a lysine bis-phosphonate deriva-
tive and incorporated these into PNA oligomers by solid
phase synthesis.
The PNAs were targeted to the aberrant splice site in
the globin intron inserted into a luciferase gene used in the
HeLa pLuc705 cell antisense splice correction assay (17).
The PNAs were delivered to the cells by lipofectamine,
and the results show a dramatically higher antisense activ-
ity of the phosphonate conjugated PNAs compared to
unmodiﬁed PNA with a clear positive correlation to the
number of phosphonate groups in the PNA oligomer (up
to 12). The bis-phosphonate conjugated PNAs were sig-
niﬁcantly more active than unmodiﬁed PNA delivered by
the published PNA/DNA heteroduplex method and
showed subnanomolar activity in the HeLa pLuc705 cell
assay. These results show that PNA oligomers conjugated
to four to six lysine bis-phosphonate units are very eﬃ-
ciently delivered to eukaryotic cells by cationic lipoplexes
and therefore hold great promise for a general, straight-
forward and robust method for delivering gene activity
modulating PNAs to eukaryotic cells in culture.
EXPERIMENTAL PROCEDURES
Synthesis ofPNA
The sequences of the PNAs are listed in Table 1. PNA
synthesis was carried out using Boc-chemistry as reported
previously (18). Glutamine phosphonate or lysine
bis-phosphonate monomers (Figure 1) were covalently
linked to PNA at the N-terminal on the solid support
via continuous synthesis using Fmoc-chemistry. The
resulting PNAs were HPLC puriﬁed and characterized
by MALDI-TOF mass spectrometry (Table 1). The
PNAs were lyophilized and stored at 48C until use.
Synthesis of glutaminephosphonate andlysine
bis-phosphonate monomers (Scheme 1)
4-[N-(Di-tert-butoxy-phosphorylmethyl)-carbamoyl]-2-
Fmoc-amino butyric acid allyl ester (1). Commercially
available Fmoc-Glu-OAll (Sigma-Aldrich, Brøndby,
Denmark) (3.2g, 8mmol) was dissolved in DMF (20ml)
under inert gas. DCC (2.4g, 12mmol) and DhbtOH (25%
solution in DMF, 6.6ml, 10mmol) were added and the
mixture was stirred for 20min. A solution of amino
methylphosphonic acid di-tert-butyl ester (19) (1.7g,
7.2mmol) in DMF (20ml) was added and the mixture
was stirred overnight under nitrogen. Insoluble solid was
removed by ﬁltration and the ﬁltrate was evaporated to
dryness under vacuum. The remaining residue was dis-
solved in EtOAc (100ml) and extracted with a saturated
aqueous solution of Na2CO3 (2 50ml) and brine
(1 50ml). The organic phase was dried over Na2SO4
and evaporated to dryness. The crude product was puriﬁed
Table 1. PNA oligomers
No. Name Sequence Mass found (calcd) (%)
a
2389 Naked-PNA H-CCTCTTACCTCAGTTACA-NH2 4767 (4765) 95+
3283 P3-PNA H-(Gln-phosphonate
b)3-eg1-CCTCTTACCTCAGTTACA-NH2 5576 (5576) 90+
3242 P7-PNA H-(Gln-phosphonate)7-eg1-CCTCTTACCTCAGTTACA-NH2 6482
f (6464) 80+
3284 P10-PNA H-(Gln-phosphonate)10-eg1-CCTCTTACCTCAGTTACA-NH2 7127
f (7128) #
3323 bP4-PNA H-(Lys-bis-phosphonate
c)4-CCTCTTACCTCAGTTACA-NH2 6181
f (6196) 95+
3324 bP5-PNA H-(Lys-bis-phosphonate)5-CCTCTTACCTCAGTTACA-NH2 6545
f (6554) 95+
3325 bP6-PNA H-(Lys-bis-phosphonate)6-CCTCTTACCTCAGTTACA-NH2 6915
f (6912) 90+
3326 Flk-bP6-PNA
d H-Flk-(Lys-bis-phosphonate)6-CCTCTTACCTCAGTTACA-NH2 7427
f (7441) 95+
2745 PNA-mismatch
e H-eg1-CCTCTGACCTCATTTACA-NH2 4911 (4910) 90+
3353 bP6-PNA-mismatch
e H-(Lys-bis-phosphonate)6-CCTCTGACCTCATTTACA-NH2 6909 (6912) 95+
aPurity (%): 95+ corresponds to single peak with slight foot; 90+ corresponds to single peak with slight foot and/or shoulder peak;
80+ corresponds to single peak with signiﬁcant foot and/or shoulder peaks; #Broad peak with shoulders, exact purity diﬃcult to estimate.
bStructure is shown in Figure 1.
cStructure is shown in Figure 1.
dFl-bP6-PNA has ﬂuorescein (Fl) attached to the "-amino group of a lysine residue (39).
eMismatch PNAs of PNA2745 and PNA3353, whereas two mismatches are underlined.
fDue to the polyanionic character pf the phosphonate-conjugated PNAs, the MALDI signal from these were quite weak and broad, and therefore
less accurate than for the unmodiﬁed PNAs.
Figure 1. Chemical structures of the glutamine phosphonate and lysine
bis-phosphonate amino acids (attached to the N-terminal of PNA).
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as a slightly yellow powder (72% yield).
1H NMR (CDCl3)
d 7.8–7.2 (m, 8H), 6.0 (d, J=8Hz, 1H), 5.8 (overlapping
m, 2H), 5.2 (m, 2H), 4.6 (m, 4H), 4.3 (m, 2H), 4.2 (m, 2H),
3.3 (m, 2H), 2.8 (m, 2H), 1.4, (2s, 18H);
13C NMR (CDCl3)
d 170.72, 169.53, 156.21, 143.90, 143.77, 141.30, 131.62,
127.72, 127.10, 125.24, 125.15, 119.98, 118.63, 83.48,
83.35, 67.28, 66.34, 50.82, 47.13, 39.62, 37.57, 33.98,
30.40 (6C), mass spectrum (FAB), m/z 615 (M+H)
+.
4-[N-(Di-tert-butoxy-phosphorylmethyl)-carbamoyl]-2-
Fmoc-amino butyric acid (2). Compund 1 (1.7g, 2mmol)
was dissolved in THF (4ml) under inert gas at ambient
temperature. N-ethylaniline (1ml) and a catalytic amount
of Pd(PPhe3)4 were added sequentially and completion of
the reaction was veriﬁed by TLC. Drop-wise addition
of the reaction mixture into stirred n-hexane (100ml)
resulted in precipitation of pure 2 (78% yield) as a slightly
yellow solid which was ﬁltered oﬀ and washed appropri-
ately with n-hexane.
1H NMR (DMSO d6) d 12.7
(br.s, 1H), 7.8-7.2 (m, 10H), 4.3 (m, 3H), 4.0 (m, 1H), 3.5
(m, 2H), 2.2 (t, J=8Hz, 2H), 1.9 (m, 2H), 1.4, (s, 18H);
13C NMR (DMSO d6) d 175.90, 171.80, 155.06, 136.08,
129.50, 129.33, 128.54, 128.45, 126.98, 126.90, 79.92,
64.78, 54.53, 50.55, 47.58, 45.20, 38.50, 29.69, 28.30 (6C);
mass spectrum (FAB), m/z 575 (M+H)
+.
3-(Di-tert-butoxy-phosphoryl)-2-(Di-tert-butoxy-
phosphorylmethyl)-propionic acid methyl ester (3).
Di-tert-butyl-phosphite (2.56g, 13.2mmol) was dissolved
in 0.5M KHMDS solution in toluene (26.4ml, 13.2mmol)
at 08C (using an ice bath) under inert gas and stirred for
15min. A solution of 3-bromo-2-bromomethyl-propionic
acid methyl ester (1.54g, 6mmol) in dry toluene (5ml) was
added through a syringe. The ice bath was removed and the
reaction mixture was stirred overnight at 258C. Volatiles
were removed under reduced pressure and the residue was
dissolved in EtOAc (100ml) and extracted successively
with a saturated aqueous solution of Na2CO3 (1 50ml)
and KHSO4 (1 50ml) and brine (1 50ml). The organic
phase was dried over Na2SO4 and solvents were removed
by evaporation to provide 3 as a colorless foam (83%
yield).
1H NMR (DMSO-d6) d 3.6 (s, 3H), 3.3 (overlapping
s, 4H), 1.9 (m, 1H), 1.4 (2s, 36H);
13C NMR (DMSO-d6)
d 173.43, 81.96, 52.56, 29.83, 27.46; mass spectrum (FAB),
m/z 487 (M+H)
+.
6-[3-(Di-tert-butoxy-phosphoryl)-2-(Di-tert-butoxy-
phosphorylmethyl)-propionylamino]-2-(9H-floren-9-
ylmethylcarboxylamino)-hexanoic acid allyl ester
(5). Compound 3 (2.4g, 5mmol) was dissolved in a mix-
ture of methanol and NaOH (2M) aqueous solution
(100ml, 1:1) and stirred for 1h at 258C. The solution
was concentrated to half of its volume at reduced pres-
sure and 408C. Remaining solution was washed with
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Scheme 1.
4426 Nucleic Acids Research, 2008, Vol. 36, No. 13diethylether (1 50ml) and acidiﬁed to pH 4 with HCl
(3M) at 08C. This solution was extracted with EtOAc
(2 100ml) and the combined organic phases were dried
over Na2SO4 and the solvents were removed under reduced
pressure to provide 4 as colorless foam (1.5g, 62%).
Freshly made foam was dissolved in DMF (20ml). DCC
(990mg, 4.8mmol) and DhbtOH (25% solution in DMF,
2.5ml, 3.8mmol) were added and the mixture was stirred
for 20min under inert gas to provide the activated car-
boxylic acid. In parallel a solution of commercially avail-
able Fmoc-lysine-OAll HCl (Iris Biotech GmbH) (1.5g,
3.8mmol) in DMF (20ml) was prepared and neutralized
by adding DIPEA (0.7ml, 4mmol) and stirring for 20min.
The neutralized solution was added into activated car-
boxylic acid solution and the mixture was stirred overnight
under inert gas. Insoluble solid was removed by ﬁltration
and the ﬁltrate was evaporated under vacuum to dryness.
The remaining residue was dissolved in EtOAc (100ml)
and extracted with saturated aqueous solution of
Na2CO3 (2 50ml) and brine (1 50ml). The organic
phase was dried over Na2SO4 and evaporated to dryness.
The crude product was puriﬁed by silica gel column
chromatography (EtOAc/methanol, 9:1) to provide 5 as a
slightly yellow powder (44% yield).
1H NMR (DMSO-d6)
d 7.8-7.3 (m, 10H), 5.8 (m, 1H), 5.3 (m, 2H), 4.6 (m, 3H),
4.3 (m, 2H), 4.0 (m, 1H), 3.3 (m, 2H), 3.0 (m, 2H), 2.7
(m, 1H), 2.0-1.7 (m, 6H), 1.6 (m, 2H), 1.4 (s, 36H);
13C
NMR (DMSO-d6) d 175.30, 172.46, 156.10, 143.70,
142.80, 140.68, 137.40, 132.36, 128.85, 127.57, 127.21,
126.98, 121.30, 120.04, 119.94, 117.57, 81.06 (4C), 65.63,
64.65, 64.27, 53.80, 46.63, 36.73, 33.30, 30.00 (12C), 28.40,
22.68; mass spectrum (FAB), m/z 863 (M+H)
+.
6-[3-(Di-tert-butoxy-phosphoryl)-2-(Di-tert-butoxy-
phosphorylmethyl)-propionylamino]-2-(9H-floren-9-
ylmethylcarboxylamino)-hexanoic acid (6). The method
for preparation of compound 2 was applied to yield com-
pound 6 (68% yield) from 5 as a slightly yellow powder.
1H NMR (DMSO-d6) d 7.9-7.3 (m, 10H), 4.5 (m, 3H),
3.9 (m, 1H), 3.3 (m, 2H), 3.0 (m, 2H), 2.7 (m, 1H),
2.0-1.7 (m, 6H), 1.6 (m, 2H), 1.4 (s, 36H);
13C NMR
(DMSO-d6) d 177.30, 172.40, 156.30, 143.76, 142.80,
140.66, 137.10, 128.60, 127.50, 127.20, 126.90, 125.22,
121.50, 120.10, 119.90, 81.07 (4C), 65.60, 64.60, 64.20,
53.80, 46.60, 36.70, 33.82, 30.08 (12C), 28.46, 21.00;
mass spectrum (FAB), m/z 823 (M+H)
+.
Cell culture
HeLa pLuc705 cells were purchased from Gene Tools
(Philomath, OR, USA). Cells were grown in RPMI1640
medium (Sigma) supplemented with 10% fetal bovine
serum (FBS, Sigma), 1% glutamax (Gibco, Invitrogen,
Carlsbad, CA, USA), 100U/ml penicillin (Gibco) and
100mg/ml streptomycin (Gibco) at 378C in humidiﬁed
air with 5% CO2. For studies of HeLa pLuc705 cells in
96-well plate format, cells were trypsinized and seeded
(1.2 10
4cells/well) 16h before treatment. For studies in
24-well plate, 7.2 10
4cells/well were used.
Celldelivery ofphosphonateconjugated PNA
The cells, replated in 96-well or 24-well plates 16–24h
earlier, were treated with 100ml/well (for 96-well plate)
or 0.3ml/well (for 24-well plate) of the PNA solution in
RPMI1640 (10% FBS, 1% glutamax) for 24h. Prepara-
tion of 0.3ml delivery solution: 60ml PNA/lipid complex
(formed by incubating 30ml of PNA solution (in water)
with 30ml of LipofectAMINE2000 (Invitrogen, Carlsbad,
CA, USA) (diluted in OPTI-MEM to a ﬁnal concentration
of LipofectAMINE2000 of 8ml/ml) for 10min at room
temperature) was mixed with 0.24ml of RPMI1640
(10% FBS, 1% glutamax). Then the cells were incubated
with this mixture for 24h at 378C and were subjected to
further analysis.
PNA/DNA heteroduplex delivery
Formation of PNA/DNA heteroduplexes was performed
as described (15), using PNA2389 and complemen-
tary DNA (50-AATATGTAACTGAGGTA-30). The
PNA/DNA heteroduplex was incubated with LipofectA-
MINE2000 in 50ml of OPTI-MEM for 15min and mixed
with 250ml of RPMI1640 (10% FBS, 1% glutamax). The
solutions were used for delivery as described above for
the phosphonate conjugated PNA.
Luciferase assay
Luciferase activity of the cells was measured by using
Bright-Glo Luciferase assay system (Promega, Madison,
WI, USA) or Luciferase Assay System (Promega) for 96-
well plate format (for screenings) or 24-well plate format,
respectively, according to the manufacture’s instructions.
Luminescent readings from 96-well plate formats (with
background subtracted) are presented as relative light
units (RLU/well) (as the amount of material does not
allow protein determinations). For the cells in 24-well
plate formats, cell were lysed with Passive Lysis buﬀer
(Promega) and used for both luciferase analysis and
RNA extraction. Luminescent readings from 24-well
format were background-subtracted and normalized by
protein concentrations and are presented as RLU/mg pro-
tein. Protein concentrations were determined by the BCA
protein assay (Pierce) according to the manufacturer’s
instruction.
RT-PCR
Total RNA was extracted from the samples in Passive
Lysis buﬀer using RNeasy Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction.
Three ng of total RNA was used for each RT-PCR reac-
tion (20ml/reaction) by using OneStep RT-PCR kit
(Qiagen). Primers for the RT-PCR were: 50-
TTGATATGTGGATTTCGAGTCGTC-30 (forward
primer) and 50-TGTCAAT-CAGAGTGCTTTTGGCG-
30 (reverse primer). The RT-PCR program was as follows:
[(558C, 35min) 1 cycle, (958C, 15min) 1 cycle, (948C,
0.5min; 558C, 0.5min; 728C, 0.5min) 26–28 cycles]. RT-
PCR DNA products were analyzed on a 2% agarose gel
with 1 TBE buﬀer and visualized by ethidium bromide
staining. Gel images were captured by ImageMaster
Nucleic Acids Research, 2008, Vol. 36, No. 13 4427(Pharmacia Biotech, Uppsala, Sweden) and analyzed by
UN-SCAN-IT software (Silk Scientiﬁc Corporation,
Orem, Utah, USA).
Confocal microscopy
Exponentially growing HeLa pLuc705 cells were plated
in 8-well Lab-Tek
TM chambered coverglass (Nunc,
Roskilde, Denmark) at a cell density of 5 10
4cells/well
the day before treatment, and treated with PNA for 24h
as described above. Following treatment, the cells were
incubated with nuclear staining dye Syto59 (Molecular
probes, 5mM) for 10min. Then the cells were washed
with Hank’s solution and immediately analysed by micro-
scopy using a MultiProbe 2001 Laser Scanning Confocal
System equipped with an Argon laser and a red laser diode
(excitation wavelength 488nm and 638nm, Radiance2000,
BioRad, Hercules, CA, USA) connected to a Nicon eclipse
TE200 microscope (oil immersion 60X1.4NA objective,
Nikon, Tokyo, Japan). The Lasersharp 2000 software
package (BioRad) was used for image acquisition and
processing.
Thermaldenaturation (Tm)
Tm measurements were performed on a Cary 300 Bio
UV-visible spectrophotometer (Varian, Cary, NC, USA)
connected to a temperature controller. Thermal melting
proﬁles were obtained in 10mM sodium phosphate
(pH 7.0) containing 0.1mM EDTA and NaCl at the desig-
nated concentration using heating–cooling cycles in the
range of 5–958C at a rate of 0.58C/min. The melting tem-
perature (Tm) was determined as the maximum of the ﬁrst
derivative of the heating curve. Cuvettes of 1.0cm path
length and 1.0ml volume were used for all experiments.
RESULTS AND DISCUSSION
Novel eﬃcient and facile methods for cellular (and not
least in vivo) delivery of antisense (RNA interference)
and antigene (DNA interference) therapeutic drugs in
general are highly warranted, and this is particularly
pertinent concerning PNA-based technologies. Cationic
transfection reagents (such as cationic lipids), which very
eﬃciently deliver negatively charged phosphodiester-
derived oligonucleotides to cells in culture, are practically
non-eﬀective for charge neutral oligomers like unmodiﬁed
PNA. However, DNA oligonucleotides may be exploited
as hybridization carriers of PNAs, and if properly opti-
mized in terms of PNA–DNA duplex stability, this
method appears as the most eﬀective for delivery of
PNA to cells in culture (15,16).
Inspired by these observations, we decided to synthesize
two readily accessible phosphonate derivatives of gluta-
mine and lysine, respectively (Figure 1, Scheme 1), as a
very convenient and general way of introducing a nega-
tively charged domain into a PNA oligomer via continu-
ous solid phase synthesis. The new amino acid monomers,
containing either a phosphonate (glutamine) or bis-
phosphonate (lysine) moiety (Figure 1), were coupled to
the N-terminus end of the PNA as a trimer, heptamer
or decamer (mono-phosphonate) or a tetra-, penta-
or hexamer (bis-phosphonate) using an antisense PNA
sequence which is targeted to an intronic aberrant
splice site of the luciferase pre-mRNA in HeLa pLuc705
cells (17).
The PNA conjugates were delivered to the HeLa
pLuc705 cells in complex with lipofectamine and the
antisense activity, which is also a measure of cellular
nuclear uptake eﬃciency, was evaluated quantitatively as
induced luciferase activity as a consequence of mRNA
splicing correction. The three PNAs, conjugated to 3, 7
or 10 units of glutamine phosphonate monomer, respec-
tively (P3-PNA, P7-PNA, P10-PNA) showed signiﬁcant
dose-dependent antisense activity via lipofectamine
delivery (Figure 2A), whereas essentially no activity was
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Figure 2. Comparison of the antisense activity of phosphonate-
conjugated PNAs with that of unmodiﬁed PNA and a PNA/DNA
heteroduplex delivered by lipofection. The phosphonate-conjugated
PNAs with 3, 7 and 10 units of phosphonate monomers (respectively
P3-PNA, P7-PNA and P10-PNA) or the PNA/DNA heteroduplex were
complexed with LipofectAMINE2000 and delivered to the HeLa
pLuc705 cells. After 24h, the cells were subjected to the further anal-
ysis. (A) Luciferase activity [using Bright-Gro assay (Promega)]. The
values represent the mean SD of three experiments. (B) RT-PCR
analysis of the mis-splicing correction of luciferase pre-mRNAs by
phosphonate-conjugated PNAs and PNA/DNA heteroduplex. U, frag-
ments without correction (268bp). (C) Fragments with mis-splicing
correction (142bp). The numbers under the ﬁgure indicate the relative
amount (%) of the corrected form to the sum of corrected form and
uncorrected form.
4428 Nucleic Acids Research, 2008, Vol. 36, No. 13found in the absence of the cationic lipid (data not
shown). The antisense activity of these PNA conjugates
showed a clear dependence on the number of phosphonate
monomers, with P10-PNA being most active exhibiting an
EC50 [concentration yielding 50% of maximum lucifer-
ase activity (and 50% splicing correction)] around 5nM.
Furthermore, the activity found for P7-PNA was compar-
able to that obtained with unmodiﬁed PNA (naked PNA)
delivered by the PNA/DNA heteroduplex lipofection
method, while P10-PNA was several fold more active.
The data obtained in the luciferase assay was quantita-
tively supported by RT-PCR analysis of mRNA splice
correction (Figure 2B). These results clearly show
that PNA–phosphonate conjugates are delivered to (the
nucleus of) HeLa pLuc705 cells with an eﬃciency that
surpasses that of the PNA/DNA mediated delivery
system.
In an attempt to further improve the phosphonate
conjugates, we synthesized a bis-phosphonate amino
acid, which reduces the number of required coupling
steps two-fold for an equivalent number of phosphonate
groups. We synthesized PNAs conjugated to 4, 5 or 6 units
of the bis-phosphonate lysine monomer, respectively at the
N-terminus end (bP4-PNA, bP5-PNA and bP6-PNA)
(Table 1) and tested these in the HeLa pLuc705
cell assay. The antisense activity of these PNAs was
compared to that of PNAs P7-PNA and P10-PNA as
well as to that of the naked PNA delivered as a PNA/
DNA heteroduplex (Figure 3A). Also in this series the
antisense activity of the bis-phosphonate conjugated
PNAs depended on the number of bis-phosphonate mono-
mers—while there were no signiﬁcant antisense activities
in the absence of the cationic lipid (data not shown)—and
all of the bis-phosphonate conjugated PNAs showed sig-
niﬁcantly higher antisense activity than the P10-PNA and
thus also than the PNA/DNA heteroduplex. Indeed the
activity of bis-P6-PNA was at least 20-fold higher than
that of the PNA/DNA duplex, and an EC50 value below
1nM was indicated.
To analyze the eﬀect of PNA–phosphonate conjugation
on nucleic acid target binding aﬃnity, thermal stabilities
of the PNAs with a complementary DNA or RNA oligo-
nucleotide were investigated (Table 2). Tm values of the
PNA–DNA/RNA complexes with phosphonate conju-
gated PNAs and bis-phosphonate conjugated PNAs were
virtually identical to that of the unmodiﬁed PNA in
100mM NaCl ( 69 and  788C for DNA and RNA,
respectively). However, as would be expected from elec-
trostatic repulsion considerations, the stability of the
phosphonate conjugated PNA–DNA duplex decreases
with decreasing ionic strength (Figure 5) as opposed to
the behavior of aegPNA–DNA duplexes (20). These
results indicate that coupling of the PNA to either phos-
phonate monomers or bis-phosphonate monomers dra-
matically improve the cellular delivery of the PNA
without aﬀecting the binding aﬃnity of the PNA to the
target sequence. Therefore, we further investigated the
cellular fate of bP6-PNA, which showed the highest
antisense activity among the PNAs tested.
Cellular uptake of bP6-PNA was analyzed by confocal
laser scanning microscopy using a ﬂuorescein-labeled
PNA (Flk-bP6-PNA). The HeLa pLuc705 cells were
treated with a Flk-bP6-PNA/lipofectamine complex for
24h and subjected to microscopy (Figure 4A and B).
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Figure 3. Comparison of the antisense activity of bis-phosphonate-
conjugated PNAs, phosphonate-conjugated PNAs and PNA/DNA
heteroduplex delivered by lipofection. Three PNAs conjugated to 4, 5
and 6 units of bis-phosphonate monomers, respectively (bP4-PNA,
bP5-PNA and bP6-PNA) and two phosphonate-conjugated PNAs
(P7-PNA, and P10-PNA) and PNA/DNA heteroduplex were com-
plexed with LipofectAMINE2000 and used for delivery to the HeLa
pLuc705 cells. After 24h, the cells were subjected to the further analysis.
(A) Luciferase activity [using Bright-Gro assay (Promega)]. The
values represent the mean SD of three experiments. (B) RT-PCR anal-
ysis of the mis-splicing correction of luciferase pre-mRNAs by phospho-
nate-conjugated PNAs. U, fragments without correction (268bp).
(C) Fragments with mis-splicing correction (142bp). The numbers
under the ﬁgure indicate the relative amount (%) of the corrected
form to the sum of corrected form and uncorrected form.
Table 2. Thermal stability (Tm) of PNA–DNA and –RNA duplexes
Antisense Oligo# Name Tm (8C)
a
Complex with
sense DNA
b
Complex with
sense RNA
c
PNA2389 Naked PNA 69.0 79.0
PNA 3283 P3-PNA 70.1 78.1
PNA3242 P7-PNA 68.0 77.2
PNA3284 P10-PNA 68.2 78.1
PNA3323 bP4-PNA 69.0 79.0
PNA3324 bP5-PNA 69.1 78.3
PNA3325 bP6-PNA 68.1 78.0
PNA2745 PNA-mismatch 45.0 59.0
PNA3353 bP6-PNA-mismatch 46.1 59.2
DNA2389
d DNA2389 58.0 60.0
20O-MeRNA
e 2OMe 56.0 75.0
aMelting temperatures of duplexes were measured in 10mM sodium
phosphate (pH 7.0) containing 100mM NaCl and 0.1mM EDTA.
bSense DNA sequence, 50-TGTAACTGAGGTAAGAGG-30.
cSense RNA sequence, 50-UGUAACUGAGGUAAGAGG-30.
dDNA2389 sequence, 50-CCTCTTACCTCAGTTACA-30.
e20O-MeRNA sequence, 50-CCUCUUACCUCAGUUACA-30.
Nucleic Acids Research, 2008, Vol. 36, No. 13 4429While the ﬂuorescence signal was only faint at 10nM
and—almost absent at the lowest PNA concentration
(3nM)—cellular uptake was clearly visible at 30 and
100nM as indicated by the even intracellular distribution
of the green ﬂuorescence appearing both in the cytosol
and in the nucleus. To conﬁrm the nuclear localization
of the PNA, the cells treated with 30nM Flk-bP6-PNA
were counter-stained in the nucleus by the nuclear staining
dye SYTO59 (Figure 4B). Co-localization of PNA (green
ﬂuorescent) and nuclear (red ﬂuorescent) staining is very
clearly observed as a yellow region on the merged image.
These results therefore show that a major fraction of the
PNA is indeed present in the nucleus.
The sequence speciﬁcity of the antisense activity
was established by using a double mismatch PNA (two
base interchange) to the bP6-PNA. This mismatched
PNA (PNA 3353) bound to complementary RNA with
signiﬁcantly reduced aﬃnity (Tm= 198C) as compared
to the fully matched PNA 3325) (Table 1), and showed
<2% antisense activity even at 300nM (Figure 6A and B).
In order to directly compare the eﬃciency of the bP6-
PNA with a compound previously used in the HeLA
pLuc705 assay, we used an analogous 20O-Me-RNA.
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Figure 6. Comparison of antisense activity of bP6-PNA with its mis-
match control (bP6-PNA-mismatch) and 20O-Me-RNA. HeLa pLuc705
cells were replated in 24-well plate the day before treatment with bP6-
PNA (PNA3325), bP6-PNA mismatch (PNA3353) or 20O-Me-RNA at
the designated concentrations in complex with LipofectAMINE2000
for 24h and subjected to the further analysis. (A) Luciferase activities
were normalized by the protein concentrations. Inserted panel is the
same data with the expansion below 100nM. The values represent the
mean SD of three experiments. (B) RT-PCR analysis of the mis-
splicing correction of luciferase pre-mRNAs by the oligo. U, fragments
without mis-splicing correction (268bp). (C) Fragments with mis-
splicing correction (142bp). The numbers under the ﬁgure indicate
the relative amount (%) of the corrected form to the sum of corrected
form and uncorrected form.
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Figure 4. Cellular uptake of bis-phosphonated-PNA (bP6-PNA) in
HeLa pLuc705 cells analyzed by confocal microscopy. (A) The cells
were treated with 3, 10, 30 or 100nM of Fl-bP6-PNA (PNA3326).
Subsequently, the cells were washed with Hank’s solution and subjected
to microscopy analysis. (B) The cells were treated with 30nM of
Fl-bP6-PNA and subsequently nuclear-stained with SYTO59 (5mM,
Molecular probes). The merged image was superimposed from the
images with green ﬁlter (FITC) and red ﬁlter (SYTO).
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Figure 5. Eﬀect of NaCl concentration on the thermal stability of
PNA/DNA duplexes. Melting temperature (Tm, 8C) of the duplexes
formed by PNA (naked PNA (PNA2389) or bP6-PNA (PNA3325)
with a complementary DNA (50-TGTAACTGAGGTAAGAGG-30)
measured in 10mM sodium phosphate (pH 7.0) containing 0.1mM
EDTA and NaCl at the designated concentration.
4430 Nucleic Acids Research, 2008, Vol. 36, No. 13In a fully parallel experiment (Figure 6) this RNA was
only slightly active giving 5% splice correction (10-fold
over background) at 300nM. Therefore, the phosphonate
conjugated PNAs, in particular the bP6-PNA, are much
more active than the corresponding 20O-Me-RNA.
Surprisingly, the activity of the 20O-Me-RNA, despite eﬃ-
cient RNA hybridization [Tm=758C (Table 2)], did not
rise beyond 5% even at higher concentrations (up to
3mM). However, in other published studies using this
RNA (21–23), only luciferase activities and not splice
correction data were reported, and judged from this data
the luciferase was activated only around 10-fold above
background, while maximum activation by the PNA pre-
sently described is  200-fold. The low activity found for
the 20O-Me-RNA could be caused by rapid degradation
due to insuﬃcient nuclease stability (24,25). Finally, it is
worth noting that none of these PNAs showed pro-
nounced toxicities above that which can be attributed to
the lipofectamine treatment (Figure S1, supplementary).
CONCLUSION
The present study shows that conjugation of phosphonate
or bis-phosphonate ligands to simple aegPNA oligomers
can signiﬁcantly improve cationic lipoplex-mediated cellu-
lar delivery and intracellular gene modulating activity of
the PNA oligomer, and most likely cellular activity of
other uncharged antisense compounds such as the mor-
pholino oligomers (26,27) should be improved through
analogous conjugation. Furthermore, such phosphonate
conjugates may be delivered by a large range of systems
developed for DNA and siRNA delivery (28–30) including
cationic polymers and dendrimers as well as nanoparticles,
which all rely on electrostatic interactions between the
antisense agent and the delivery vehicle.
In terms of cellular delivery the presently described
phosphonate conjugated PNAs may be compared
with the PNA–DNA chimera or with the more advanced
alternating backbone hydroyprolyl/phosphono PNA
(‘HypPNA–pPNA’), which have shown promising proper-
ties both in cell culture (11,12) as well as in vivo using
a peptide delivery vehicle (31). However, the conjugation
strategy described here allows sensitive cellular activity
testing and screening of basically unmodiﬁed aegPNA
(as the phosphonate peptide is essentially a carrier) in
order to optimize for gene and sequence target. It will
also be straightforward to prepare ‘prodrug’ type of
conjugates in which the phosphonate peptide is cleaved
oﬀ by an esterase (32) or in a reductive environment
(via disulﬁde linkage). In further developments toward
medical drugs it may well be advantageous to entirely
change delivery strategy for in vivo applications using
nanoparticles, carrier peptides or other yet undiscovered
modalities, and the phosphonate amino acids may even be
included as components in such a strategy. The phospho-
nate peptide strategy thus increases the ﬂexibility for
future in vivo bioavailability optimization and should be
considered a complementary strategy to the employment
of e.g. cell penetrating peptides (CPPs) (33,34). The latter
may eventually be developed for eﬀective in vivo medical
use, but are so far severely limited by relatively low
potency due to endosomal trapping (35,36) (typically
EC50 values around 1mM is found) as well as signiﬁ-
cant toxicity. However, novel peptide motifs showing
improved cell delivery properties are continuously being
discovered (37,38).
Finally, and most importantly the results show that
biological activities in the sub-nanomolar range of phos-
phonate peptide PNA conjugates are obtainable. Thus the
intracellular eﬃcacy of aegPNA oligomers rival that of
siRNA and the results therefore emphasize that provided
suﬃcient in vivo bioavailability of (derivatives of) aegPNA
can be achieved these molecules may be developed into
potent gene therapeutic drugs.
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